The mRNA sequencing market size is expected to grow from US$ 1.356 billion in 2022 to US$ 3.662 billion by 2030.

Factors such as the identification of mRNA sequencing for diagnosis of rare diseases and innovative product launches propel the mRNA sequencing market growth.

mRNA Sequencing in Drug Development Drives Market Growth

Drug discovery and development have undergone a remarkable transformation with the advent of single-cell RNA sequencing (scRNA-seq). scRNA-seq aids in the identification and validation of potential drug targets by characterizing the gene expression of individual disease cells. Therefore, by studying the transcriptomic profiles of healthy and diseased cells by scRNA-seq, researchers can identify specific cell types and identify disease progression. Also, the transcriptome information can guide in the selection of therapeutic target agents and help prioritize molecules for further development to provide valuable insights related to the action mechanism of drugs. Further, scRNA-seq can enable more accurate patient stratification and matching individuals with targeted therapies, thereby resulting in monitoring drug response and disease progression at the cellular level. Therefore, scRNA-seq will provide new market avenues for biotechnology companies to account for considerable revenue growth in terms of drug discovery and development in the coming years.

Market Trend

Exploring mRNA Sequencing Applications in Various Fields

mRNA sequencing has applications in single-cell sequencing for in-depth cellular investigation, spatial transcriptomics for mapping gene expression in tissues, and personalized medicine for customized treatments based on individual genetic profiles. mRNA sequencing requires understanding disease causes, finding biomarkers, and researching gene expression. By shedding light on intricate biological processes, mRNA sequencing is enhancing the fields of neuroscience, cancer immunotherapy, and infectious disease research.

Moreover, mRNA vaccines show great promise as a fast-developing, safe, and inexpensive alternative to traditional vaccination methods due to their high potency and possibility for safe administration. Numerous mRNA vaccination platforms against cancer and infectious diseases have shown promising outcomes in animal and human models. Thus, emerging applications will bring new mRNA sequencing market trends in the coming years.

mRNA Sequencing Market, by Product:

Based on product, the mRNA sequencing market analysis is carried out by considering the following segments: products and services. The product segment is further classified into instruments and consumables. The consumables segment held largest market share in 2022. High-throughput mRNA sequencing is a standard technique for transcriptome discovery and identifying differential gene expression analysis in life science laboratories. Therefore, innovative product launches by manufacturers will enhance the growth of the consumables segment. PacBio's "SMRTbell prep kit 3.0 and binding kits 3.1 and 3.2" are examples of innovative consumables used for mRNA sequencing. In October 2023, PacBio announced product launches for the development of high-quality and accurate sequencing solutions, "Kinnex RNA kits." The Kinnex RNA kits increase throughput for full-length RNA, single-cell RNA, and 16S rRNA sequencing. These Kinnex kits are based on the "MAS-seq methods" where customers can transcribe long chain libraries to short , increase throughput, and make the sequencing process more cost-effective.

mRNA Sequencing Market, by Method:

The market is segmented by methods such as first-generation sequencing, next-generation sequencing (NGS), and third-generation sequencing. The next-generation sequencing (NGS) segment held the largest mRNA sequencing market share in 2022 and is anticipated to register the highest CAGR of 13.5% during the forecast period. NGS-based mRNA sequencing is a powerful method providing several advantages over traditional methods for transcriptome analysis. For example, NGS-based mRNA sequencing is a cost-effective process, including direct quantification and identification of transcripts, and provides sensitive and accurate measurement of gene expression. Therefore, the cost-effectiveness of NGS-based mRNA sequencing is an influential factor responsible for segment growth from 2022 to 2030.

Competitive Landscape and Key Companies:

Takara Bio Inc., Illumina, Inc., QIAGEN, F. Hoffmann-La Roche Ltd, Quantabio, Zymo Research Corporation, baseclick GmbH, Paragon Genomics, Inc., Yeasen Biotechnology (Shanghai) Co., Ltd. Novogene Co, Ltd and Norgen Biotek Corp are the prominent companies in the mRNA sequencing market report. These companies focus on new technologies, upgrading existing products, and geographic expansions to meet the growing consumer demand worldwide.